
zzso has been evaluated in six phase I studies involving a total of 234 patients with a wide variety of zzso types zzso had breast or zzso zzso The aims of these studies were to determine the optimal dosage schedule of zzso for use in subsequent phase II studies, and to zzso the zzso and zzso profiles of zzso zzso zzso doses of zzso zzso zzso were administered in various treatment schedules for a total of 790 zzso zzso were repeated every 2-3 zzso zzso zzso was the major zzso adverse effect of zzso Other adverse events reported included zzso fluid zzso skin zzso zzso and zzso zzso reactions occurred zzso No abnormal cardiac activity was zzso and neurological adverse events were zzso zzso 100 zzso administered as a 1 h zzso infusion every 3 weeks combined acceptable zzso with complete zzso zzso This dosage schedule was thus considered to be optimal for further investigation in phase II zzso 

